A father's plea: The FDA needs to make sure that Juno's lethal disaster isn't repeated
The FDA never has publicly explained just why it decided to lift a clinical hold on Juno’s lead CAR-T drug JCAR015 just days after the stunning news that the trial was being halted after three patients taking the cell therapy died of a cerebral edema. But then, it never does, citing secrecy rules that frequently keep regulators silent.
Now the father of one of those victims has joined in a petition from the Center for Responsible Science seeking some real transparency at the FDA on the way it handles patient deaths — with major implications for the people who participate in clinical trials.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters